More tools:Markets·Screener·Research·Chat

TherapeuticsMD, Inc. (TXMD) Financial Statements

TherapeuticsMD, Inc.
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001SDVKL6
XNAS · usd
2.12▼ 0.02 (-0.93%)
As of 2026-09-09
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close2.14
Day's Range2.12 – 2.21
52-Week Range0.99 – 2.95
Volume14.6K
Avg Volume28.3K
Share Statistics
Shares Outstanding
Employees1
ExchangeXNAS
Listed2002-01-28
Share count as of August 9, 2026
Loading Income Statement…
Key questions about TherapeuticsMD, Inc. (TXMD)
What is TherapeuticsMD, Inc.'s Market Cap?
TherapeuticsMD, Inc.'s Market Cap is $24.5M, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s Trailing P/E?
TherapeuticsMD, Inc.'s Trailing P/E is 137.1×, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s Price / Sales?
TherapeuticsMD, Inc.'s Price / Sales is 7.3×, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s Revenue (TTM)?
TherapeuticsMD, Inc.'s Revenue (TTM) is $3.4M, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s Net Income (TTM)?
TherapeuticsMD, Inc.'s Net Income (TTM) is $179.0K, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s EBITDA?
TherapeuticsMD, Inc.'s EBITDA is -$3.4M, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s Diluted EPS (TTM)?
TherapeuticsMD, Inc.'s Diluted EPS (TTM) is 0.02, based on as-reported figures from SEC (XBRL) filings.
What is TherapeuticsMD, Inc.'s EBITDA Margin?
TherapeuticsMD, Inc.'s EBITDA Margin is -102.9%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue, net:
License revenue
YoY growth-8.7%+84.2%+33.9%+43.3%
Operating expenses:
General and administrative
Write-off of patents—
Depreciation & amortization
Total operating expenses
% of revenue193.9%199.9%273.8%209.9%
Loss from operations
% of revenue-93.9%-99.9%-173.8%-109.9%
Other income:
Interest income, net——
Sublease income
Miscellaneous income
Total other income, net
Income (loss) from continuing operations before income taxes
Income tax benefit———
Income (loss) from continuing operations, net of income taxes
Income (loss) from discontinued operations, net of income taxes
Net income (loss)
% of revenue17.8%13.1%-69.3%19.4%
Net income (loss) per common share, basic (in Dollars per share)
Net income (loss) per common share, diluted (in Dollars per share)